Chair in e-Health, Digital Systems and Life Sciences
The e-Health, Digital Systems and Life Sciences Chair is fully aligned with these new challenges of connected medicine and co-innovation, drawing on Yncrea's areas of excellence to provide original solutions within the framework of agile partnerships.
It is therefore defined as a space where micro technologies (microfluidics and lab-on-a-chip), IoT (Internet of Things) for data collection and AI (artificial intelligence) for data processing converge in a broad field of biology and health.
This space provides the multidisciplinary scientific and technical support that is sorely lacking today for the development of devices, the creation and emergence of start-ups to fully exploit the expectations and possibilities of biotechnologies.
The Chair organizes this convergence by bringing together the expertise of the Yncréa group's schools and the ecosystem of incubators in the life sciences sector, with the support of hospitals and players in the health sector.
In order to best meet its objectives, the chair is managed by a committee made up of the directors of the three ISEN schools of the Yncréa group and the director of research and innovation of Junia. The activities are regularly evaluated by an international scientific council composed of renowned academic and industrial actors.
Offers related to the Chair
E-health (or digital health) refers to "the application of information and communication technologies to all health-related activities". At the convergence of two fields undergoing rapid development and change, digital health covers a vast field of activity, organized around major axes:
- Health information systems enabling better coordination of care within a healthcare establishment (Hospital Information Systems or HIS, Electronic Patient Record or DPI, etc.) or a healthcare territory (Health Information Systems or HIS, Electronic Patient Record or DPI, etc.).) or within a healthcare region (shared healthcare information systems)
- Telemedicine, which offers remote care and covers 5 categories of medical procedures: teleconsultation, telerexpertise, telemonitoring, teleassistance, and medical regulation (center 15)
- Telehealth integrating monitoring and prevention services for individuals with a primary objective of well-being (connected objects, self-measurement mobile applications, web platforms, etc.) Depending on the users, it is possible to distinguish three types of generic technological devices within these fields of application
- Patient-centric or general public technological devices: m-health or m-santé (M for Mobile) mobile health applications, web health applications, connected objects, social networks (patient communities), health information portals, etc.
- Technological devices focused on healthcare providers such as healthcare establishments and professionals: internal HIS, shared information systems, on-board information systems (e.g. SMUR), telemedicine devices, etc.
- Technological systems centered on insurance companies, public regulators and industry: generic customer relationship management (CRM) tools, as well as datamining (internal data) and big data (external data), enabling the collection, storage and algorithmic processing of massive healthcare data.
In 2020, the national strategy for the development of digital healthcare is based on four main priorities:
- develop connected medicine through a "big data" plan for healthcare. By way of example, this plan will enable the development of new applications for remote monitoring or interpretation of medical data to assist doctors in their diagnoses;
- encourage co-innovation between healthcare professionals, citizens and economic players through the launch of calls for projects dedicated to e-health or the development of living labs in order to imagine, in direct contact with users, the medicine of tomorrow;
- simplify administrative procedures for patients (admission, online appointment booking, etc.) and equip healthcare democracy with the tools needed to promote digital health.) and equip healthcare democracy with a digital platform facilitating user consultation and participation;
- strengthen the security of healthcare information systems through a dedicated action plan.
Actions related to the Chair
In the academic field, the Chair is helping to enrich Yncrea's new training courses in its area of expertise: the generation, collection and processing of life science data. By way of example, these exchanges have enriched the definition of Master's cycles extending the Bachelor's cycle in digital science for biology (numbio) in Lille.
In research and development, our activities concern both the study and the realization of micro-fluidic or laboratory-on-a-chip devices, and the implementation of A.I. algorithms for the analysis of images or video, to help in decision-making.
For example, lab-on-a-chip allows the synthesis of biological reactions, in vitro analysis of human cell infection by pathogens or organ growth on a chip for drug candidate screening.
On the software side, artificial intelligence analyses have made it possible to develop algorithms to assist in the reading of thoracic images for the diagnosis of COVID-19 or to assist in the decision making process for the analysis of puncture products in pathology.
For industrial partnerships, we are involved in upstream studies with companies in the field of human and animal health, participate in the scientific councils of SMEs, and stimulate the creation of start-ups in close collaboration with bio-incubators.
The Chair Advisory Board
The international supervisory board is made up of personalities who are very involved in the scientific fields of the Chair, and their opinions provide real international expertise.
Karl BOHRINGER, University of Washington, Seattle, USA
Hiroyuki FUJITA, Canon Medical System corporation, Director of Advanced Research Laboratory Japan (Pioneer in Sciences)
Dr Stanislav KARSTEN, CEO Neuro-Indx, L.A., USA (entrepreneur, Biologist)
Eric LARTIGAU, General Director of Centre Oscar Lambret (MD)
Dr Nathalie MAUBON, CEO, HCS Pharma, Lille, France (contractor)
Jean-Paul SEGARD, President Fundation Norbert Segard
Dr Etienne VERVACKE, Director, EURASANTE (in contact)
Andrew YEH, Deputy Executive Secretary, Office of Science and Technology, Taiwan Republic of China
